Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib plus exemestane versus exemestane alone in second-line HR-positive HER2-negative advanced or metastatic breast cancer
2008-002457-20Phase 2Completed
- Sponsor
- Wyeth
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Bosutinib + exemestane with Exemestane alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2008; status: completed.
02
Drugs
bosutinibexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-002457-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002457-20.